Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures--Worldwide, '97-'00.
D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects*; D016273:Occupational Exposure; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine